Thermo Fisher SCIENTIFIC

SelectScreen™ Biochemical Kinase Profiling Service

Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 1 of 39

ASSAY THEORY							3
Z'-LYTE ASSAY (CONDI	TIONS					4
Z'-LYTE ASSAY	CONTR	ROLS					5
Z'-LYTE DATA A	NALYS	is					6
KINASE-SPECIFI	C ASS	AY CONDITIONS - D	DIREC	T FORMAT			7
ABL1	7	DYRK1B	13	KIT V559D V654A	19	PLK2	25
ABL1 E255K	7	DYRK3	13	KIT V560G	19	PLK3	26
ABL1 F317I	7	DYRK4	13	KSR2	19	PRKACA (PKA) PRKCA (PKC alpha)	26
ABL1 F317L ABL1 G250E	7 7	EEF2K EGFR (ErbB1)	13 13	LCK LTK (TYK1)	20 20	PRKCB1 (PKC alpha)	26 26
ABL1 T315I	7	EGFR (ErbB1) C797S	13	LYNA	20	PRKCB2 (PKC beta II)	26
ABL1 Y253F	7	EGFR (ErbB1) G719C	13	LYN B	20	PRKCD (PKC delta)	26
ABL2 (Arg)	7	EGFR (ErbB1) G719S	14	MAP3K19 (YSK4)	20	PRKCE (PKC epsilon)	26
ACVR1B (ALK4) ADRBK1 (GRK2)	7	EGFR (ErbB1) L858R EGFR (ErbB1) L861Q	14 14	MAP3K9 (MLK1) MAP4K2 (GCK)	20 20	PRKCG (PKC gamma) PRKCH (PKC eta)	26 26
ADRBK2 (GRK3)	7	EGFR (ErbB1) T790M	14	MAP4K4 (HGK)	20	PRKCI (PKC iota)	26
AKT1 (PKB alpha)	8	EGFR (ErbB1) T790M C797S L858R	14	MAP4K5 (KHS1)	20	PRKCN (PKD3)	27
AKT2 (PKB beta)	8	EGFR (ErbB1) T790M L858R	14	MAPK1 (ERK2) MAPK11 (p38 beta)	20	PRKCQ (PKC theta) PRKCZ (PKC zeta)	27 27
AKT3 (PKB gamma) ALK	8	EPHA1 EPHA2	14 14	MAPK11 (p36 beta) MAPK12 (p38 gamma)	20 21	PRKD1 (PKC zeta) PRKD1 (PKC mu)	27
AMPK (A1/B2/G2)	8	EPHA4	14	MAPK13 (p38 delta)	21	PRKD2 (PKD2)	27
AMPK (A1/B2/G3)	8	EPHA5	14	MAPK14 (p38 alpha) Direct	21	PRKG1 `	27
AMPK (A2/B1/G2) AMPK (A2/B1/G3)	8	EPHA8 EPHB1	15 15	MAPK3 (ERK1) MAPK7 (ERK5)	21 21	PRKG2 (PKG2) PRKX	27 27
AMPK (A2/B1/G3)	8	EPHB2	15	MAPKAPK2	21	PTK2 (FAK)	27
AMPK A1/B1/G1	8	EPHB3	15	MAPKAPK3	21	PTK2B (FAK2)	27
AMPK A2/B1/G1	8	EPHB4	15	MAPKAPK5 (PRAK)	21	PTK6 (Brk)	27
AURKA (Aurora A) AURKB (Aurora B)	9	ERBB2 (HER2) ERBB4 (HER4)	15 15	MARK1 (MARK) MARK2	21 21	RET RET A883F	28 28
AURKC (Aurora C)	ý	FER	15	MARK3	21	RET S891A	28
AXL	9	FES (FPS)	15	MARK4	22	RET V804E	28
BLK BMX	9	FGFR1 FGFR2	15 15	MATK (HYL) MELK	22 22	RET V804L RET Y791F	28 28
BRSK1 (SAD1)	9	FGFR2 N549H	16	MERTK (cMER)	22	ROCK1	28
BTK	9	FGFR3	16	MET (cMet)	22	ROCK2	28
CAMK1D (CaMKI delta) CAMK1G (CAMKI gamma)	9	FGFR3 K650E FGFR3 V555M	16 16	MET (cMet) Y1235D MET M1250T	22 22	ROS1 RPS6KA1 (RSK1)	28 28
CAMK16 (CAMKI ganina) CAMK2A (CaMKII alpha)	9	FGFR4	16	MINK1	22	RPS6KA2 (RSK3)	28
CAMK2B (CaMKII beta)	10	FGR	16	MKNK1 (MNK1)	22 22	RPS6KA3 (RSK2)	28
CAMK2D (CaMKII delta)	10	FLT1 (VEGFR1)	16	MST1R (RON) MST4	22	RPS6KA4 (MSK2)	29
CAMK4 (CaMKIV) CDC42 BPA (MRCKA)	10 10	FLT3 FLT3 D835Y	16 16	MUSK	22 23	RPS6KA5 (MSK1) RPS6KA6 (RSK4)	29 29
CDC42 BPB (MRCKB)	10	FLT4 (VEGFR3)	16	MYLK2 (skMLCK)	23	RPS6KB1 (p70S6K)	29
CDC42 BPG (MRCKG)	10	FRAP1 (mTOR)	17	NEK1	23	RPS6KB2 (p70S6Kb)	29
CDK1/cyclin B CDK17/cyclin Y	10 10	FRK (PŤK5) FYN	17 17	NEK2 NEK4	23 23	SBK1 SGK (SGK1)	29 29
CDK18/cyclin Y	10	GRK4	17	NEK6	23	SGK2	29
CDK2/cyclin A CDK5/p25	10 10	GRK5 GRK6	17 17	NEK9 NIM1K	23 23	SGKL (SGK3) SNF1LK2	29 29
CDK5/p25 CDK5/p35	11	GRK7	17	NTRK1 (TRKA)	23	SRC	29
CDKL5	11	GSK3A (GSK3 alpha)	17	NTRK2 (TRKB)	23	SRC N1	30
CHEK1 (CHK1) CHEK2 (CHK2)	11 11	GSK3B (GSK3 beta)	17 17	NTRK3 (TRKC) PAK1	23 24	SRMS (Srm) SRPK1	30 30
CLK1	11	HIPK1 (Myak)	17	PAK2 (PAK65)	24	SRPK2	30
CLK2	11	HIPK2	18	PAK3	24	STK22B (TSSK2)	30
CLK3 CSF1R (FMS)	11	HIPK3 (YAK1) HIPK4	18	PAK4 PAK6	24	STK22D (TSSK1) STK23 (MSSK1)	30
CSF (FMS)	11 11	IGF1R	18 18	PAKO PAK7 (KIAA1264)	24 24	STK23 (MSSK1) STK24 (MST3)	30 30
CSNK1A1 (CK1 alpha 1)	11	IKBKB (IKK beta)	18	PASK` '	24	STK25 (YSK1)	30
CSNK1A1L	11	IKBKE (IKK epsilon)	18	PDGFRA (PDGFR alpha)	24	STK3 (MST2)	30
CSNK1D (CK1 delta) CSNK1E (CK1 epsilon)	12 12	INSR INSRR (IRR)	18 18	PDGFRA D842V PDGFRA T674I	24 24	STK4 (MST1) SYK	30 31
CSNK1E (CK1 epsilon) R178C	12	IRAK4	18	PDGFRA V561D	24	TAOK2 (TAO1)	31
CSNK1G1 (CK1 gamma 1)	12	ITK	18	PDGFRB (PDGFR beta)	25	TBK1	31
CSNK1G2 (CK1 gamma 2)	12	JAK1	18 19	PDK1 Direct	25	TEK (Tie2)	31
CSNK1G3 (CK1 gamma 3) CSNK2A1 (CK2 alpha 1)	12 12	JAK2 JAK2 JH1 JH2	19 19	PEAK1 PHKG1	25 25	TEK (TIE2) Y897S TNK1	31 31
CSNK2A2 (CK2 alpha 2)	12	JAK2 JH1 JH2 V617F	19	PHKG2	25	TXK	31
DAPK3 (ZIPK)	12	JAK3	19	PIM1	25	TYK2	31
DCAMKL1 (DCLK1) DCAMKL2 (DCK2)	12 13	KDR (VEGFR2) KIT	19 19	PIM2 PIM3	25 25	TYRO3 (RSE) YES1	31 31
DNA-PK	13	KIT T670I	19	PKN1 (PRK1)	25	ZAP70	31
DVDK1A	13	KIT V559D	10	PI K1	25		



SelectScreen™ Biochemical Kinase Profi	ling Service
Z'-LYTE™ Screening Protocol and Assay	Conditions Revised 23-Jan-2018
	Page 2 of 30

BRAF	32	MAP2K2 (MEK2)	32	MAPK10 (JNK3)	32	MAPK9 (JNK2)	33
BRAF V599E MAP2K1 (MEK1)	32 32	MAP2K6 (MKK6) MAP3K8 (COT)	32 32	MAPK14 (p38 alpha) MAPK8 (JNK1)	32 32	PDK1 RAF1 (cRAF) Y340D Y341D	33 33
, ,				, ,		, ,	



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 3 of 39

Assay Theory

The Z´-LYTE biochemical assay employs a fluorescence-based, coupled-enzyme format and is based on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage (Figure 1). The peptide substrate is labeled with two fluorophores—one at each end—that make up a FRET pair.

In the primary reaction, the kinase transfers the gamma-phosphate of ATP to a single tyrosine, serine or threonine residue in a synthetic FRET-peptide. In the secondary reaction, a site-specific protease recognizes and cleaves non-phosphorylated FRET-peptides. Phosphorylation of FRET-peptides suppresses cleavage by the Development Reagent. Cleavage disrupts FRET between the donor (i.e., coumarin) and acceptor (i.e., fluorescein) fluorophores on the FRET-peptide, whereas uncleaved, phosphorylated FRET-peptides maintain FRET. A ratiometric method, which calculates the ratio (the Emission Ratio) of donor emission to acceptor emission after excitation of the donor fluorophore at 400 nm, is used to quantitate reaction progress, as shown in the equation below.

Emission Ratio = Coumarin Emission (445 nm)
Fluorescein Emission (520 nm)

A significant benefit of this ratiometric method for quantitating reaction progress is the elimination of well-to-well variations in FRET-peptide concentration and signal intensities. As a result, the assay yields very high Z'-factor values (>0.7) at a low percent phosphorylation.

Both cleaved and uncleaved FRET-peptides contribute to the fluorescence signals and therefore to the Emission Ratio. The extent of phosphorylation of the FRET-peptide can be calculated from the Emission Ratio. The Emission Ratio will remain low if the FRET-peptide is phosphorylated (i.e., no kinase inhibition) and will be high if the FRET-peptide is non-phosphorylated (i.e., kinase inhibition).




Figure 1: Z'-LYTE Illustration



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 4 of 39

Z'-LYTE Assay Conditions

Test Compounds

The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer's choosing.

Peptide/Kinase Mixtures

All Peptide/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer (see section *Kinase Specific Assay Conditions* for a complete description).

ATP Solution

All ATP Solutions are diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl₂, 1 mM EGTA).

ATP Km apparent is previously determined using a Z´-LYTE assay.

Development Reagent Solution

The Development Reagent is diluted in Development Buffer (see section *Kinase-Specific Assay Conditions - Direct and Cascade* for a complete description).

10X Novel PKC Lipid Mix: 2 mg/ml Phosphatidyl Serine, 0.2 mg/ml DAG in 20 mM HEPES, pH 7.4, 0.3% CHAPS

For 5 mL 10X Novel PKC Lipid Mix:

- 1. Add 10 mgs Phosphatidyl Serine (Avanti Polar Lipids Part# 8400032C or 840039C) and 1 mg DAG (Avanti Polar Lipids Part# 800811C) to a glass tube.
- 2. Remove the chloroform from lipid mixture by evaporating to a clear, thin film under a stream of nitrogen. Continuous rotation of the tube, at an angle to ensure maximum surface area of the lipid solution, will promote the thinnest film.
- 3. Add 5 mLs resuspension buffer, 20 mM HEPES, 0.3% CHAPS, pH 7.4, to the dried lipid mix
- 4. Heat gently to 50-60 °C for 1-2 minutes and vortex in short intervals until the lipids are dissolved to a clear or slightly hazy solution. The lipids are typically in solution after 2-3 heat/vortex cycles.
- 5. Cool to room temperature, aliquot into single use volumes and store at -20 °C.

Assay Protocol

Bar-coded Corning, low volume NBS, black 384-well plate (Corning Cat. #4514)

- 1. 100 nL 100X Test Compound in 100% DMSO
- 2. 2.4 μL Kinase buffer
- 3. 5 μL 2X Peptide/Kinase Mixture
- 4. 2.5 µL 4X ATP Solution
- 5. 30-second plate shake
- 6. 60-minute Kinase Reaction incubation at room temperature
- 7. 5 μL Development Reagent Solution
- 8. 30-second plate shake
- 9. 60-minute Development Reaction incubation at room temperature
- 10. Read on fluorescence plate reader and analyze the data



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 5 of 39

Z'-LYTE Assay Controls

The following controls are made for each individual kinase and are located on the same plate as the kinase:

0% Phosphorylation Control (100% Inhibition Control)

The maximum Emission Ratio is established by the 0% Phosphorylation Control (100% Inhibition Control), which contains no ATP and therefore exhibits no kinase activity. This control yields 100% cleaved peptide in the Development Reaction.

100% Phosphorylation Control

The 100% Phosphorylation Control, which consists of a synthetically phosphorylated peptide of the same sequence as the peptide substrate, is designed to allow for the calculation of percent phosphorylation. This control yields a very low percentage of cleaved peptide in the Development Reaction.

The 0% Phosphorylation and 100% Phosphorylation Controls allow one to calculate the percent Phosphorylation achieved in a specific reaction well. Control wells do not include any kinase inhibitors.

0% Inhibition Control

The minimum Emission Ratio in a screen is established by the 0% Inhibition Control, which contains active kinase. This control is designed to produce a 10–50%* phosphorylated peptide in the Kinase Reaction.

Known Inhibitor

A known inhibitor control standard curve, 10 point titration, is run for each individual kinase on the same plate as the kinase to ensure the kinase is inhibited within an expected IC₅₀ range previously determined.

The following controls are prepared for each concentration of Test Compound assayed:

Development Reaction Interference

The Development Reaction Interference is established by comparing the Test Compound Control wells that do not contain ATP versus the 0% Phosphorylation Control (which does not contain the Test Compound). The expected value for a non-interfering compound should be 100%. Any value outside of 90% to 110% is flagged.

Test Compound Fluorescence Interference

The Test Compound Fluorescence Interference is determined by comparing the Test Compound Control wells that do not contain the Kinase/Peptide Mixture (zero peptide control) versus the 0% Inhibition Control. The expected value for a non-fluorescence compound should be 0%. Any value > 20% is flagged.

^{*} Cascade assays may produce up to 70% phosphorylated peptide.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 6 of 39

Z'-LYTE Data Analysis

The following equations are used for each set of data points:

	Equation
Correction for Background Fluorescence	FI Sample – FI TCFI Ctl
Emission Ratio (using values corrected for background fluorescence)	Coumarin Emission (445 nm) Fluorescein Emission (520 nm)
% Phosphorylation (% Phos)	$\left\{ 1 - \frac{(Emission Ratio x F_{100\%}) - C_{100\%}}{(C_{0\%} - C_{100\%}) + [Emission Ratio x (F_{100\%} - F_{0\%})]} \right\} * 100$
% Inhibition	\[\begin{pmatrix} \text{ \choose Phos Sample} \\ \text{\choose Phos \text{\choose (\choose Inhibition Ctl)}} \end{pmatrix} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Z ' (using Emission Ratio values)	1 - 3*Stdev _{0% Phos Ctl} + 3*Stdev _{0% Inhibition} Mean _{0% Phos Ctl} - Mean _{0% Inhibition}
Difference Between Data Points (single point only)	% Inhibition Point 1 - % Inhibition Point 2
Development Reaction Interference (DRI) (no ATP control)	Emission Ratio DRI Ctl Emission Ratio 0% Phos Ctl
Test Compound Fluorescence Interference (TCFI) (check both Coumarin and Fluorescein emissions)	FI TCFI Ctl FI 0% Inhibitor Ctl

FI = Fluorescence Intensity

 $C_{100\%}$ = Average Coumarin emission signal of the 100% Phos. Control

 $C_{0\%}$ = Average Coumarin emission signal of the 0% Phos. Control

 $\mathbf{F}_{100\%} = \text{Average Fluorescein emission signal of the } 100\% \text{ Phos. Control}$

 $\mathbf{F}_{0\%}$ = Average Fluorescein emission signal of the 0% Phos. Control

DRI = Development Reaction Interference

TCFI = Test Compound Fluorescence Interference

Graphing Software

SelectScreen Kinase Profiling Service uses XLfit from IDBS. The dose response curve is curve fit to model number 205 (sigmoidal dose-response model). If the bottom of the curve does not fit between -20% & 20% inhibition, it is set to 0% inhibition. If the top of the curve does not fit between 70% and 130% inhibition, it is set to 100% inhibition.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 7 of 39

Kinase-Specific Assay Conditions - Direct Format

ABL₁

The 2X ABL1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.31 - 2 ng ABL1 and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

ABL1 E255K

The 2X ABL1 E255K / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.75 - 4.06 ng ABL1 E255K and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

ABL1 F317I

The 2X ABL1 F317I / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.65 - 8 ng ABL1 F317I and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

ABL1 F317L

The 2X ABL1 F317L / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.5 - 5 ng ABL1 F317L and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

ABL1 G250E

The 2X ABL1 G250E / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.62 - 4.28 ng ABL1 G250E and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

ABL1 T315I

The 2X ABL1 T315I / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.36 - 12 ng ABL1 T315I and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

ABL1 Y253F

The 2X ABL1 Y253F / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.73 - 5.76 ng ABL1 Y253F and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

ABL2 (Arg)

The 2X ABL2 (Arg) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.42 - 5.3 ng ABL2 (Arg) and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

ACVR1B (ALK4)

The 2X ACVR1B (ALK4) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 9.15 - 60 ng ACVR1B (ALK4) and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

ADRBK1 (GRK2)

The 2X ADRBK1 (GRK2) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.86 - 67.2 ng ADRBK1 (GRK2) and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

ADRBK2 (GRK3)

The 2X ADRBK2 (GRK3) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 9.8 - 39.7 ng ADRBK2 (GRK3) and 2 μ M Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 8 of 39

AKT1 (PKB alpha)

The 2X AKT1 (PKB alpha) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.82 - 12 ng AKT1 (PKB alpha) and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AKT2 (PKB beta)

The 2X AKT2 (PKB beta) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.78 - 40 ng AKT2 (PKB beta) and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AKT3 (PKB gamma)

The 2X AKT3 (PKB gamma) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.5 - 8.3 ng AKT3 (PKB gamma) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

<u>ALK</u>

The 2X ALK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 4.25 - 96 ng ALK and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

AMPK (A1/B2/G2)

The 2X AMPK (A1/B2/G2) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.32 - 2.4 ng AMPK (A1/B2/G2) and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AMPK (A1/B2/G3)

The 2X AMPK (A1/B2/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.77 - 5.2 ng AMPK (A1/B2/G3) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

AMPK (A2/B1/G2)

The 2X AMPK (A2/B1/G2) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.66 - 5.24 ng AMPK (A2/B1/G2) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

AMPK (A2/B1/G3)

The 2X AMPK (A2/B1/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.48 - 15.8 ng AMPK (A2/B1/G3) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

AMPK (A2/B2/G3)

The 2X AMPK (A2/B2/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 1.19 - 15.2 ng AMPK (A2/B2/G3) and 2 μ M Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

AMPK A1/B1/G1

The 2X AMPK A1/B1/G1 / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.21 - 2.86 ng AMPK A1/B1/G1 and 2 µM Ser/Thr 23 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AMPK A2/B1/G1

The 2X AMPK A2/B1/G1 / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.75 - 40 ng AMPK A2/B1/G1 and 2 μ M Ser/Thr 23 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 9 of 39

AURKA (Aurora A)

The 2X AURKA (Aurora A) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.75 - 3.64 ng AURKA (Aurora A) and 2 µM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AURKB (Aurora B)

The 2X AURKB (Aurora B) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.5 - 34.8 ng AURKB (Aurora B) and 2 µM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

AURKC (Aurora C)

The 2X AURKC (Aurora C) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 7.44 - 100 ng AURKC (Aurora C) and 2 μM Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

<u>AXL</u>

The 2X AXL / Tyr 06 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 2 - 40 ng AXL and 2 μ M Tyr 06 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

BLK

The 2X BLK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.08 - 0.75 ng BLK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

BMX

The 2X BMX / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.5 - 45.9 ng BMX and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

BRSK1 (SAD1)

The 2X BRSK1 (SAD1) / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.8 - 41.7 ng BRSK1 (SAD1) and 2 μ M Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

BTK

The 2X BTK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.04 - 10.4 ng BTK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

CAMK1D (CaMKI delta)

The 2X CAMK1D (CaMKI delta) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 15.9 - 133 ng CAMK1D (CaMKI delta) and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

CAMK1G (CAMKI gamma)

The 2X CAMK1G (CAMKI gamma) / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 7.5 - 30 ng CAMK1G (CAMKI gamma) and 2 µM Ser/Thr 23 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

CAMK2A (CaMKII alpha)

The 2X CAMK2A (CaMKII alpha) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.27 - 1.2 ng CAMK2A (CaMKII alpha) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 10 of 39

CAMK2B (CaMKII beta)

The 2X CAMK2B (CaMKII beta) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 0.17 - 4.15 ng CAMK2B (CaMKII beta) and 2 µM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

CAMK2D (CaMKII delta)

The 2X CAMK2D (CaMKII delta) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 0.08 - 0.67 ng CAMK2D (CaMKII delta) and 2 µM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

CAMK4 (CaMKIV)

The 2X CAMK4 (CaMKIV) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 9.84 - 60 ng CAMK4 (CaMKIV) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

CDC42 BPA (MRCKA)

The 2X CDC42 BPA (MRCKA) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 9.75 - 57.4 ng CDC42 BPA (MRCKA) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

CDC42 BPB (MRCKB)

The 2X CDC42 BPB (MRCKB) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.59 - 21.7 ng CDC42 BPB (MRCKB) and 2 µM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

CDC42 BPG (MRCKG)

The 2X CDC42 BPG (MRCKG) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.5 - 25 ng CDC42 BPG (MRCKG) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

CDK1/cyclin B

The 2X CDK1/cyclin B / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.5 - 46.4 ng CDK1/cyclin B and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

CDK17/cyclin Y

The 2X CDK17/cyclin Y / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.44 - 30 ng CDK17/cyclin Y and 2 μ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

CDK18/cyclin Y

The 2X CDK18/cyclin Y / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.46 - 30 ng CDK18/cyclin Y and 2 μ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

CDK2/cyclin A

The 2X CDK2/cyclin A / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.22 - 10.3 ng CDK2/cyclin A and 2 μM Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

CDK5/p25

The 2X CDK5/p25 / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.18 - 2 ng CDK5/p25 and 2 μM Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 11 of 39

CDK5/p35

The 2X CDK5/p35 / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.14 - 1.3 ng CDK5/p35 and 2 μM Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

CDKL5

The 2X CDKL5 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 10 - 40 ng CDKL5 and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

CHEK1 (CHK1)

The 2X CHEK1 (CHK1) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.38 - 100 ng CHEK1 (CHK1) and 2 μ M Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

CHEK2 (CHK2)

The 2X CHEK2 (CHK2) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.51 - 40 ng CHEK2 (CHK2) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

CLK1

The 2X CLK1 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 15 - 120 ng CLK1 and 2 µM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:512 dilution of Development Reagent A is added.

CLK2

The 2X CLK2 / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.97 - 32 ng CLK2 and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

CLK3

The 2X CLK3 / Ser/Thr 18 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 9.57 - 41.5 ng CLK3 and 2 μ M Ser/Thr 18 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

CSF1R (FMS

The 2X CSF1R (FMS) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.2 - 40 ng CSF1R (FMS) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

CSK

The 2X CSK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.5 - 35.4 ng CSK and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

CSNK1A1 (CK1 alpha 1)

The 2X CSNK1A1 (CK1 alpha 1) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 2.6 - 13.5 ng CSNK1A1 (CK1 alpha 1) and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

CSNK1A1L

The 2X CSNK1A1L / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 8.75 - 40 ng CSNK1A1L and 2 μ M Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 12 of 39

CSNK1D (CK1 delta)

The 2X CSNK1D (CK1 delta) / Ser/Thr 11 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 9.97 - 72.9 ng CSNK1D (CK1 delta) and 2 μ M Ser/Thr 11 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.

CSNK1E (CK1 epsilon)

The 2X CSNK1E (CK1 epsilon) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.35 - 9.44 ng CSNK1E (CK1 epsilon) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

CSNK1E (CK1 epsilon) R178C

The 2X CSNK1E (CK1 epsilon) R178C / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.75 - 60 ng CSNK1E (CK1 epsilon) R178C and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

CSNK1G1 (CK1 gamma 1)

The 2X CSNK1G1 (CK1 gamma 1) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.75 - 8.54 ng CSNK1G1 (CK1 gamma 1) and 2 μ M Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

CSNK1G2 (CK1 gamma 2)

The 2X CSNK1G2 (CK1 gamma 2) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.5 - 12 ng CSNK1G2 (CK1 gamma 2) and 2 µM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

CSNK1G3 (CK1 gamma 3)

The 2X CSNK1G3 (CK1 gamma 3) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.25 - 17.5 ng CSNK1G3 (CK1 gamma 3) and 2 μM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

CSNK2A1 (CK2 alpha 1)

The 2X CSNK2A1 (CK2 alpha 1) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.68 - 25.7 ng CSNK2A1 (CK2 alpha 1) and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

CSNK2A2 (CK2 alpha 2)

The 2X CSNK2A2 (CK2 alpha 2) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.6 - 31.5 ng CSNK2A2 (CK2 alpha 2) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

DAPK3 (ZIPK)

The 2X DAPK3 (ZIPK) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.63 - 34.4 ng DAPK3 (ZIPK) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

DCAMKL1 (DCLK1)

The 2X DCAMKL1 (DCLK1) / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.75 - 15 ng DCAMKL1 (DCLK1) and 2 μ M Ser/Thr 23 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 13 of 39

DCAMKL2 (DCK2)

The 2X DCAMKL2 (DCK2) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 8.8 - 50.4 ng DCAMKL2 (DCK2) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

DNA-PK

The 2X DNA-PK / Ser/Thr 26 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 5.0 μ g/ml CT-DNA. The final 10 μ L Kinase Reaction consists of 3.88 - 27.3 ng DNA-PK and 2 μ M Ser/Thr 26 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 2.5 μ g/ml CT-DNA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.

DYRK1A

The 2X DYRK1A / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.77 - 12.5 ng DYRK1A and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

DYRK1B

The 2X DYRK1B / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 0.47 - 5.84 ng DYRK1B and 2 µM Ser/Thr 18 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

DYRK3

The 2X DYRK3 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.93 - 5.38 ng DYRK3 and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added.

DYRK4

The 2X DYRK4 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 9.4 - 74.1 ng DYRK4 and 2 μ M Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:512 dilution of Development Reagent A is added.

EEF2K

The $\overline{2X}$ EEF2K / Ser/Thr 24 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 11 - 47.7 ng EEF2K and 2 μ M Ser/Thr 24 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16384 dilution of Development Reagent A is added.

EGFR (ErbB1)

The 2X EGFR (ErbB1) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.1 - 8 ng EGFR (ErbB1) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) C797S

The 2X EGFR (ErbB1) C797S / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 2 - 14 ng EGFR (ErbB1) C797S and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) G719C

The 2X EGFR (ErbB1) G719C / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 6.25 - 35 ng EGFR (ErbB1) G719C and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 14 of 39

EGFR (ErbB1) G719S

The 2X EGFR (ErbB1) G719S / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.75 - 60 ng EGFR (ErbB1) G719S and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) L858R

The 2X EGFR (ErbB1) L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 0.2 - 3.36 ng EGFR (ErbB1) L858R and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) L861Q

The 2X EGFR (ErbB1) L861Q / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.31 - 11.2 ng EGFR (ErbB1) L861Q and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) T790M

The 2X EGFR (ErbB1) T790M / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.9 - 40 ng EGFR (ErbB1) T790M and 2 μM Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) T790M C797S L858R

The 2X EGFR (ErbB1) T790M C797S L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 1 - 6 ng EGFR (ErbB1) T790M C797S L858R and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

EGFR (ErbB1) T790M L858R

The 2X EGFR (ErbB1) T790M L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.25 - 2.08 ng EGFR (ErbB1) T790M L858R and 2 μ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

EPHA1

The 2X EPHA1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3.12 - 45.2 ng EPHA1 and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

EPHA2

The 2X EPHA2 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.1 - 40 ng EPHA2 and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

EPHA4

The 2X EPHA4 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.42 - 21.7 ng EPHA4 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

EPHA5

The 2X EPHA5 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.18 - 38.1 ng EPHA5 and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 15 of 39

EPHA8

The 2X EPHA8 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.2 - 24.6 ng EPHA8 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

EPHB1

The 2X EPHB1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.39 - 39.4 ng EPHB1 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

EPHB2

The 2X EPHB2 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.55 - 36 ng EPHB2 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

EPHB3

The 2X EPHB3 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.78 - 43.8 ng EPHB3 and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

EPHB4

The 2X EPHB4 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.68 - 18 ng EPHB4 and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

ERBB2 (HER2)

The 2X ERBB2 (HER2) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 1.78 - 30.4 ng ERBB2 (HER2) and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

ERBB4 (HER4)

The 2X ERBB4 (HER4) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 2 - 20 ng ERBB4 (HER4) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

FER

The 2X FER / Tyr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.25 - 6.82 ng FER and 2 μM Tyr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

FES (FPS)

The 2X FES (FPS) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.65 - 5.21 ng FES (FPS) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

FGFR1

The 2X FGFR1 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.45 - 2.45 ng FGFR1 and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FGFR2

The 2X FGFR2 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.19 - 1.99 ng FGFR2 and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 16 of 39

FGFR2 N549H

The 2X FGFR2 N549H / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.55 - 7 ng FGFR2 N549H and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FGFR3

The 2X FGFR3 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.5 - 14 ng FGFR3 and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FGFR3 K650E

The 2X FGFR3 K650E / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.6 - 6 ng FGFR3 K650E and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FGFR3 V555M

The 2X FGFR3 V555M / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1 - 8 ng FGFR3 V555M and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FGFR4

The 2X FGFR4 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 2.44 - 84 ng FGFR4 and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

FGR

The 2X FGR / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 5.9 ng FGR and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

FLT1 (VEGFR1)

The 2X FLT1 (VEGFR1) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.64 - 12.5 ng FLT1 (VEGFR1) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

FLT3

The 2X FLT3 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.4 - 28 ng FLT3 and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

FLT3 D835Y

The 2X FLT3 D835Y / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.03 - 1.48 ng FLT3 D835Y and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

FLT4 (VEGFR3)

The 2X FLT4 (VEGFR3) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 2 - 20 ng FLT4 (VEGFR3) and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 17 of 39

FRAP1 (mTOR)

The 2X FRAP1 (mTOR) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 11.1 - 80 ng FRAP1 (mTOR) and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

FRK (PTK5)

The 2X FRK (PTK5) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.1 - 51.9 ng FRK (PTK5) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

FYN

The 2X FYN / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.44 - 45.6 ng FYN and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

GRK4

The 2X GRK4 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.79 - 3.76 ng GRK4 and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

GRK5

The 2X GRK5 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 4.23 - 38.4 ng GRK5 and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

GRK6

The 2X GRK6 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 11.2 - 61.8 ng GRK6 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

GRK7

The 2X GRK7 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.88 - 23 ng GRK7 and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

GSK3A (GSK3 alpha)

The 2X GSK3A (GSK3 alpha) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.21 - 1.69 ng GSK3A (GSK3 alpha) and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added.

GSK3B (GSK3 beta)

The 2X GSK3B (GSK3 beta) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.12 - 0.7 ng GSK3B (GSK3 beta) and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added.

HCK

The 2X HCK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.09 - 1.5 ng HCK and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

HIPK1 (Myak)

The 2X HIPK1 (Myak) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.48 - 29.3 ng HIPK1 (Myak) and 2 μ M Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:512 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 18 of 39

HIPK2

The 2X HIPK2 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3.53 - 19 ng HIPK2 and 2 μ M Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:512 dilution of Development Reagent A is added.

HIPK3 (YAK1)

The 2X HIPK3 (YAK1) / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 8.75 - 40 ng HIPK3 (YAK1) and 2 μ M Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

HIPK4

The 2X HIPK4 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3 - 35.5 ng HIPK4 and 2 µM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

IGF1R

The 2X IGF1R / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 10 - 160 ng IGF1R and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

IKBKB (IKK beta)

The 2X IKBKB (IKK beta) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.93 - 12 ng IKBKB (IKK beta) and 2 µM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

IKBKE (IKK epsilon)

The 2X IKBKE (IKK epsilon) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.65 - 10.6 ng IKBKE (IKK epsilon) and 2 μ M Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.

INSR

The 2X INSR / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.94 - 50 ng INSR and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

INSRR (IRR)

The 2X INSRR (IRR) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 2.19 - 13.9 ng INSRR (IRR) and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

IRAK4

The 2X IRAK4 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.45 - 63.6 ng IRAK4 and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

<u>ITK</u>

The 2X ITK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.69 - 67.1 ng ITK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

JAK1

The 2X JAK1 / Tyr 06 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 21.2 - 91.5 ng JAK1 and 2 μ M Tyr 06 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 19 of 39

JAK2

The 2X JAK2 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.05 - 0.42 ng JAK2 and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

JAK2 JH1 JH2

The 2X JAK2 JH1 JH2 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.64 - 2.98 ng JAK2 JH1 JH2 and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

JAK2 JH1 JH2 V617F

The 2X JAK2 JH1 JH2 V617F / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 7.38 - 100 ng JAK2 JH1 JH2 V617F and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

JAK3

The 2X JAK3 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.5 - 3.58 ng JAK3 and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

KDR (VEGFR2)

The 2X KDR (VEGFR2) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 15 ng KDR (VEGFR2) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

KIT

The 2X KIT / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.17 - 16 ng KIT and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

KIT T670

The 2X KIT T670I / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 6 - 113 ng KIT T670I and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

KIT V559D

The 2X KIT V559D / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.64 - 30 ng KIT V559D and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

KIT V559D V654A

The 2X KIT V559D V654A / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 8.75 - 50 ng KIT V559D V654A and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

KIT V560G

The 2X KIT V560G / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 40 ng KIT V560G and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

KSR2

The 2X KSR2 / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.06 - 6 ng KSR2 and 2 μ M Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 20 of 39

LCK

The 2X LCK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 8.25 - 100 ng LCK and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

LTK (TYK1)

The 2X LTK (TYK1) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.78 - 55.5 ng LTK (TYK1) and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

<u>LYN A</u>

The 2X LYN A / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.75 - 20 ng LYN A and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

LYN B

The 2X LYN B / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.85 - 14.8 ng LYN B and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

MAP3K19 (YSK4)

The 2X MAP3K19 (YSK4) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.06 - 9.5 ng MAP3K19 (YSK4) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

MAP3K9 (MLK1)

The 2X MAP3K9 (MLK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 27 ng MAP3K9 (MLK1) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

MAP4K2 (GCK)

The 2X MAP4K2 (GCK) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.17 - 3 ng MAP4K2 (GCK) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

MAP4K4 (HGK)

The 2X MAP4K4 (HGK) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.36 - 3 ng MAP4K4 (HGK) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

MAP4K5 (KHS1)

The 2X MAP4K5 (KHS1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.25 - 4.5 ng MAP4K5 (KHS1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

MAPK1 (ERK2)

The 2X MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2 - 45.5 ng MAPK1 (ERK2) and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAPK11 (p38 beta)

The 2X MAPK11 (p38 beta) / Ser/Thr 15 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 7.1 - 42.6 ng MAPK11 (p38 beta) and 2 μ M Ser/Thr 15 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 21 of 39

MAPK12 (p38 gamma)

The 2X MAPK12 $\overline{\text{(p38 gamma)}}$ / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.47 - 3.26 ng MAPK12 (p38 gamma) and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAPK13 (p38 delta)

The 2X MAPK13 (p38 delta) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.22 - 36.6 ng MAPK13 (p38 delta) and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAPK14 (p38 alpha) Direct

The 2X MAPK14 (p38 alpha) / Ser/Thr 15 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 7.07 - 51.4 ng MAPK14 (p38 alpha) and 2 μ M Ser/Thr 15 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

MAPK3 (ERK1)

The 2X MAPK3 (ERK1) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 5.94 - 94.5 ng MAPK3 (ERK1) and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAPK7 (ERK5)

The 2X MAPK7 (ERK5) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.51 - 12.7 ng MAPK7 (ERK5) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAPKAPK2

The 2X MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.04 - 0.18 ng MAPKAPK2 and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAPKAPK3

The 2X MAPKAPK3 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.09 - 2.05 ng MAPKAPK3 and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAPKAPK5 (PRAK)

The 2X MAPKAPK5 (PRAK) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.29 - 8.32 ng MAPKAPK5 (PRAK) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MARK1 (MARK)

The 2X MARK1 (MARK) / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 14.9 - 168 ng MARK1 (MARK) and 2 µM Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

MARK2

The 2X MARK2 / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 37.2 - 149 ng MARK2 and 2 μ M Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

MARK3

The 2X MARK3 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.32 - 2.4 ng MARK3 and 2 μ M Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 22 of 39

MARK4

The 2X MARK4 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.54 - 2.36 ng MARK4 and 2 μ M Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

MATK (HYL)

The 2X MATK (HYL) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 4.06 - 117 ng MATK (HYL) and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

MELK

The 2X MELK / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.76 - 6.48 ng MELK and 2 µM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

MERTK (cMER)

The 2X MERTK (cMER) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.68 - 6.22 ng MERTK (cMER) and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

MET (cMet)

The 2X MET (cMet) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.49 - 7.84 ng MET (cMet) and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

MET (cMet) Y1235D

The 2X MET (cMet) Y1235D / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.55 - 6 ng MET (cMet) Y1235D and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

MET M1250T

The 2X MET M1250T / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3 - 16.2 ng MET M1250T and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

MINK1

The 2X MINK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.9 - 19.6 ng MINK1 and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

MKNK1 (MNK1)

The 2X MKNK1 (MNK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 16 - 63.8 ng MKNK1 (MNK1) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

MST1R (RON)

The 2X MST1R (RON) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.25 - 1.18 ng MST1R (RON) and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

MST4

The 2X MST4 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 6 - 50 ng MST4 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 23 of 39

MUSK

The 2X MUSK / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 21.3 - 134 ng MUSK and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

MYLK2 (skMLCK)

The 2X MYLK2 (skMLCK) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.13 - 15 ng MYLK2 (skMLCK) and 2 μ M Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

NEK1

The 2X NEK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.3 - 80 ng NEK1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

NEK2

The 2X NEK2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.75 - 5.4 ng NEK2 and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

NEK4

The 2X NEK4 / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 4 - 18.1 ng NEK4 and 2 μ M Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

NEK

The 2X NEK6 / Ser/Thr 22 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.13 - 22 ng NEK6 and 2 µM Ser/Thr 22 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:8192 dilution of Development Reagent A is added.

NEK9

The 2X NEK9 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 1.44 - 22.4 ng NEK9 and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

NIM1K

The 2X NIM1K / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.28 - 20 ng NIM1K and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

NTRK1 (TRKA)

The 2X NTRK1 (TRKA) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 6 - 88.7 ng NTRK1 (TRKA) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

NTRK2 (TRKB)

The 2X NTRK2 (TRKB) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 0.34 - 5.46 ng NTRK2 (TRKB) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

NTRK3 (TRKC)

The 2X NTRK3 (TRKC) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.33 - 45.1 ng NTRK3 (TRKC) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 24 of 39

PAK1

The 2X PAK1 / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.71 - 30.8 ng PAK1 and 2 μ M Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

PAK2 (PAK65)

The 2X PAK2 (PAK65) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.29 - 6 ng PAK2 (PAK65) and 2 μ M Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

PAK3

The 2X PAK3 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.38 - 22 ng PAK3 and 2 µM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

PAK4

The 2X PAK4 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.1 - 0.75 ng PAK4 and 2 μ M Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

PAK6

The 2X PAK6 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.38 - 7.38 ng PAK6 and 2 μM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

PAK7 (KIAA1264)

The 2X PAK7 (KIAA1264) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.05 - 0.5 ng PAK7 (KIAA1264) and 2 µM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

PASK

The 2X PASK / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3.6 - 15.4 ng PASK and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PDGFRA (PDGFR alpha)

The 2X PDGFRA (PDGFR alpha) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.54 - 22.6 ng PDGFRA (PDGFR alpha) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

PDGFRA D842V

The 2X PDGFRA D842V / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 3.49 - 22.4 ng PDGFRA D842V and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

PDGFRA T674I

The 2X PDGFRA T674I / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 7.5 - 30 ng PDGFRA T674I and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

PDGFRA V561D

The 2X PDGFRA V561D / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.5 - 12 ng PDGFRA V561D and 2 μ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 25 of 39

PDGFRB (PDGFR beta)

The 2X PDGFRB (PDGFR beta) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 7 - 50 ng PDGFRB (PDGFR beta) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

PDK1 Direct

The 2X PDK1 / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 5.15 - 30 ng PDK1 and 2 μ M Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PEAK1

The 2X PEAK1 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 2.73 - 40 ng PEAK1 and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

PHKG1

The 2X PHKG1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 2.13 - 15 ng PHKG1 and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PHKG2

The 2X PHKG2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.3 - 10.1 ng PHKG2 and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

PIM1

The 2X PIM1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.3 - 13.9 ng PIM1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

PIM₂

The 2X PIM2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.44 - 6.86 ng PIM2 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

PIM3

The 2X PIM3 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 0.38 - 50 ng PIM3 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

PKN1 (PRK1)

The 2X PKN1 (PRK1) / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3 - 60 ng PKN1 (PRK1) and 2 μM Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

PLK1

The 2X PLK1 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.98 - 26 ng PLK1 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

PLK₂

The 2X PLK2 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 9.59 - 160 ng PLK2 and 2 μ M Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 26 of 39

PLK₃

The 2X PLK3 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.27 - 1.8 ng PLK3 and 2 μ M Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.

PRKACA (PKA)

The 2X PRKACA (PKA) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.01 - 0.14 ng PRKACA (PKA) and 2 μ M Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

PRKCA (PKC alpha)

The 2X PRKCA (PKC alpha) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.02 - 0.16 ng PRKCA (PKC alpha) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCB1 (PKC beta I)

The 2X PRKCB1 (PKC beta I) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.02 - 0.58 ng PRKCB1 (PKC beta I) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

PRKCB2 (PKC beta II)

The 2X PRKCB2 (PKC beta II) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.04 - 0.56 ng PRKCB2 (PKC beta II) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCD (PKC delta)

The 2X PRKCD (PKC delta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.23 - 1.32 ng PRKCD (PKC delta) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCE (PKC epsilon)

The 2X PRKCE (PKC epsilon) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.57 - 2.7 ng PRKCE (PKC epsilon) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

PRKCG (PKC gamma)

The 2X PRKCG (PKC gamma) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.03 - 0.24 ng PRKCG (PKC gamma) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCH (PKC eta)

The 2X PRKCH (PKC eta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.29 - 6 ng PRKCH (PKC eta) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCI (PKC iota)

The 2X PRKCI (PKC iota) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 1.25 - 6 ng PRKCI (PKC iota) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 27 of 39

PRKCN (PKD3)

The 2X PRKCN (PKD3) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.25 - 40 ng PRKCN (PKD3) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

PRKCQ (PKC theta)

The 2X PRKCQ (PKC theta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 0.04 - 0.36 ng PRKCQ (PKC theta) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

PRKCZ (PKC zeta)

The 2X PRKCZ (PKC zeta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 2.8 - 12.7 ng PRKCZ (PKC zeta) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

PRKD1 (PKC mu)

The 2X PRKD1 (PKC mu) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.56 - 7.8 ng PRKD1 (PKC mu) and 2 μ M Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:256 dilution of Development Reagent A is added.

PRKD2 (PKD2)

The 2X PRKD2 (PKD2) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.64 - 5.84 ng PRKD2 (PKD2) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

PRKG1

The 2X PRKG1 / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 20 μM cGMP. The final 10 μL Kinase Reaction consists of 0.17 - 1 ng PRKG1 and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 10 μM cGMP. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

PRKG2 (PKG2)

The 2X PRKG2 (PKG2) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 20 μM cGMP. The final 10 μL Kinase Reaction consists of 0.1 - 1.4 ng PRKG2 (PKG2) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 10 μM cGMP. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

PRKX

The 2X PRKX / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.75 - 4.98 ng PRKX and 2 µM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

PTK2 (FAK

The 2X PTK2 (FAK) / Tyr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 12.5 - 100 ng PTK2 (FAK) and 2 μ M Tyr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.

PTK2B (FAK2)

The 2X PTK2B (FAK2) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 5.26 - 45.9 ng PTK2B (FAK2) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

PTK6 (Brk)

The 2X PTK6 (Brk) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 11.8 - 65 ng PTK6 (Brk) and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 28 of 39

RET

The 2X RET / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.49 - 3.64 ng RET and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

RET A883F

The 2X RET A883F / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 1.02 - 6.74 ng RET A883F and 2 μ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

RET S891A

The 2X RET S891A / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.15 - 1.2 ng RET S891A and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

RET V804E

The 2X RET V804E / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3 - 20 ng RET V804E and 2 μ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:64 dilution of Development Reagent B is added.

RET V804L

The 2X RET V804L / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.52 - 4.74 ng RET V804L and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

RET Y791F

The 2X RET Y791F / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.86 - 6.16 ng RET Y791F and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

ROCK1

The 2X ROCK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.1 - 8 ng ROCK1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

ROCK2

The 2X ROCK2 / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.58 - 4.13 ng ROCK2 and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

ROS1

The $\overline{2}X$ ROS1 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.63 - 12 ng ROS1 and 2 μ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent B is added.

RPS6KA1 (RSK1)

The 2X RPS6KA1 (RSK1) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.51 - 22.3 ng RPS6KA1 (RSK1) and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

RPS6KA2 (RSK3)

The 2X RPS6KA2 (RSK3) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.5 - 9 ng RPS6KA2 (RSK3) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

RPS6KA3 (RSK2)

The 2X RPS6KA3 (RSK2) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.1 - 0.48 ng RPS6KA3 (RSK2) and 2 μ M Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 29 of 39

RPS6KA4 (MSK2)

The 2X RPS6KA4 (MSK2) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.1 - 23.4 ng RPS6KA4 (MSK2) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

RPS6KA5 (MSK1)

The 2X RPS6KA5 (MSK1) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.23 - 2.84 ng RPS6KA5 (MSK1) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

RPS6KA6 (RSK4)

The 2X RPS6KA6 (RSK4) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.19 - 2.5 ng RPS6KA6 (RSK4) and 2 µM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

RPS6KB1 (p70S6K)

The 2X RPS6KB1 (p70S6K) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.87 - 17.7 ng RPS6KB1 (p70S6K) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

RPS6KB2 (p70S6Kb)

The 2X RPS6KB2 (p70S6Kb) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 10 - 70 ng RPS6KB2 (p70S6Kb) and 2 μM Ser/Thr 19 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

SBK

The 2X SBK1 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 2.79 - 15 ng SBK1 and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

SGK (SGK1)

The 2X SGK (SGK1) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.09 - 1 ng SGK (SGK1) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

SGK₂

The 2X SGK2 / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.21 - 3 ng SGK2 and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

SGKL (SGK3)

The 2X SGKL (SGK3) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.19 - 1.26 ng SGKL (SGK3) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

SNF1LK2

The 2X SNF1LK2 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.62 - 9.94 ng SNF1LK2 and 2 μ M Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

SRC

The 2X SRC / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.54 - 36 ng SRC and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 30 of 39

SRC N1

The 2X SRC N1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1 - 15.5 ng SRC N1 and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

SRMS (Srm)

The 2X SRMS (Srm) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2 - 8.97 ng SRMS (Srm) and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

<u>SRPK1</u>

The 2X SRPK1 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.74 - 37 ng SRPK1 and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

SRPK2

The 2X SRPK2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3.76 - 46.8 ng SRPK2 and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.

STK22B (TSSK2)

The 2X STK22B (TSSK2) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 5.55 - 47.2 ng STK22B (TSSK2) and 2 µM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

STK22D (TSSK1)

The 2X STK22D (TSSK1) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.69 - 12.2 ng STK22D (TSSK1) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

STK23 (MSSK1)

The 2X STK23 (MSSK1) / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 5.69 - 26.2 ng STK23 (MSSK1) and 2 µM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

STK24 (MST3)

The 2X STK24 (MST3) / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 14.7 - 59.4 ng STK24 (MST3) and 2 μM Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added

STK25 (YSK1)

The 2X STK25 (YSK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.34 - 37.5 ng STK25 (YSK1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

STK3 (MST2)

The 2X STK3 (MST2) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 6.25 - 38.7 ng STK3 (MST2) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

STK4 (MST1)

The 2X STK4 (MST1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 6.25 - 160 ng STK4 (MST1) and 2 μ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:45000 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 31 of 39

SYK

The 2X SYK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.69 - 5.35 ng SYK and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

TAOK2 (TAO1)

The 2X TAOK2 (TAO1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.4 - 11 ng TAOK2 (TAO1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

TBK1

The 2X TBK1 / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.93 - 13 ng TBK1 and 2 µM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

TEK (Tie2)

The 2X TEK (Tie2) / Tyr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 1 - 6 ng TEK (Tie2) and 2 μ M Tyr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

TEK (TIE2) Y897S

The 2X TEK (TIE2) Y897S / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.38 - 16 ng TEK (TIE2) Y897S and 2 μ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

TNK1

The 2X TNK1 / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 10 - 40 ng TNK1 and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

TXK

The 2X TXK / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.38 - 93.6 ng TXK and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

TYK2

The 2X TYK2 / Tyr 03 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 20 - 120 ng TYK2 and 2 μ M Tyr 03 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:4096 dilution of Development Reagent A is added.

TYRO3 (RSE)

The 2X TYRO3 (RSE) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.15 - 25.8 ng TYRO3 (RSE) and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

YES1

The 2X YES1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.75 - 4.5 ng YES1 and 2 μ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:128 dilution of Development Reagent A is added.

<u>ZAP70</u>

The 2X ZAP70 / Tyr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 20.3 - 126 ng ZAP70 and 2 μ M Tyr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:16 dilution of Development Reagent B is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 32 of 39

Kinase-Specific Assay Conditions - Cascade Format

BRAF

The 2X BRAF / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.04 - 0.15 ng BRAF, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 µM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

BRAF V599E

The 2X BRAF V599E / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.003 - 0.01 ng BRAF V599E, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAP2K1 (MEK1)

The 2X MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.06 - 0.25 ng MAP2K1 (MEK1), 105 ng inactive MAPK1 (ERK2), and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAP2K2 (MEK2)

The 2X MAP2K2 (MEK2) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.15 - 0.6 ng MAP2K2 (MEK2), 105 ng inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAP2K6 (MKK6)

The 2X MAP2K6 (MKK6) / inactive MAPK12 (p38 gamma) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.92 - 7.67 ng MAP2K6 (MKK6), 100 ng inactive MAPK12 (p38 gamma), and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAP3K8 (COT)

The 2X MAP3K8 (COT) / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1 - 4 ng MAP3K8 (COT), 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAPK10 (JNK3)

The 2X MAPK10 (JNK3) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.96 - 3.86 ng MAPK10 (JNK3), 12.5 ng inactive MAPKAPK2, and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

MAPK14 (p38 alpha)

The 2X MAPK14 (p38 alpha) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.003 - 0.01 ng MAPK14 (p38 alpha), 6.5 ng inactive MAPKAPK2, and 2 μ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

MAPK8 (JNK1)

The 2X MAPK8 (JNK1) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 0.62 - 2.5 ng MAPK8 (JNK1), 25 ng inactive MAPKAPK2, and 2 μ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 33 of 39

MAPK9 (JNK2)

The 2X MAPK9 (JNK2) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μ L Kinase Reaction consists of 0.57 - 2.3 ng MAPK9 (JNK2), 12.5 ng inactive MAPKAPK2, and 2 μ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.

PDK1

The 2X PDK1 / inactive AKT2 (PKB beta) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 5 - 20 ng PDK1, 150 ng inactive AKT2 (PKB beta), and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

RAF1 (cRAF) Y340D Y341D

The 2X RAF1 (cRAF) Y340D Y341D / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.006 - 0.02 ng RAF1 (cRAF) Y340D Y341D, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 μ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of a 1:1024 dilution of Development Reagent A is added.



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 34 of 39

Table of Kinase ATP Km Bins and Inhibitor Validation

The table below provides specifications and data around each kinase. The representative IC50 value with a known inhibitor for each kinase was determined at the ATP bin nearest to the ATP Km app, unless indicated with an asterisk (*) in which case the IC50 value was determined at 100 µM ATP.

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
ABL1	Tyr 02	12	10	Tyrphostin AG1478	303
ABL1 E255K	Tyr 02	4.2	5	Staurosporine	75.2
ABL1 F317I	Tyr 02	15	10	Staurosporine	189
ABL1 F317L	Tyr 02	14	10	Staurosporine	182
ABL1 G250E	Tyr 02	5.4	5	Staurosporine	34.1
ABL1 T315I	Tyr 02	2.8	5	Staurosporine	11.5
ABL1 Y253F	Tyr 02	11.8	10	Staurosporine	47.0
ABL2 (Arg)	Tyr 02	30	25	Tyrphostin AG1478	804
ACVR1B (ALK4)	Ser/Thr 16	1.6	5	SB 431542	638
ADRBK1 (GRK2)	Ser/Thr 16	13.3	10	Staurosporine	1170
ADRBK2 (GRK3)	Ser/Thr 16	11.7	10	Staurosporine	1380
AKT1 (PKB alpha)	Ser/Thr 06	75	75	Staurosporine	11.1
AKT2 (PKB beta)	Ser/Thr 06	200	200	Staurosporine	46.9
AKT3 (PKB gamma)	Ser/Thr 06	100	100	Staurosporine	10.2
ALK	Tyr 01	30	25	Staurosporine	16.6
AMPK (A1/B2/G2)	Ser/Thr 25	9	10	Staurosporine	0.257
AMPK (A1/B2/G3)	Ser/Thr 25	13	10	Staurosporine	0.755
AMPK (A2/B1/G2)	Ser/Thr 25	11	10	Staurosporine	0.458
AMPK (A2/B1/G3)	Ser/Thr 25	24	25	Staurosporine	0.818
AMPK (A2/B2/G3)	Ser/Thr 25	40	50	Staurosporine	0.346
AMPK À1/B1/G1	Ser/Thr 23	43	50	Staurosporine	0.226
AMPK A2/B1/G1	Ser/Thr 23	148	150	Staurosporine	0.688
AURKA (Aurora A)	Ser/Thr 01	10	10	Staurosporine	3.43
AURKB (Aurora B)	Ser/Thr 01	81	75	Staurosporine	4.75
AURKC (Aurora C)	Ser/Thr 19	26	25	Staurosporine	5.41
AXL ´	Tyr 06	71	75	Staurosporine	3.37
BLK	Tyr 01	30	25	Tyrphostin AG1478	775
BMX	Tyr 01	107	100	Staurosporine	14.5
BRAF	Ser/Thr 03	Cascade	100	Staurosporine	23.6 *
BRAF V599E	Ser/Thr 03	Cascade	100	Staurosporine	31.6 *
BRSK1 (SAD1)	Ser/Thr 21	32	25	Staurosporine	2.05
BTK	Tyr 01	36	25	Tyrphostin AG1478	1990
CAMK1D (CaMKI delta)	Ser/Thr 25	28	25	Staurosporine	20.4
CAMK1G (CAMKI gamma)	Ser/Thr 23	294	300	Staurosporine	13.3
CAMK2A (CaMKII alpha)	Ser/Thr 04	10	10	Staurosporine	0.617
CAMK2B (CaMKII beta)	Ser/Thr 17	76	75	Staurosporine	0.586
CAMK2D (CaMKII delta)	Ser/Thr 04	6	5	Staurosporine	0.289
CAMK4 (CaMKIV)	Ser/Thr 13	18	25	Staurosporine	81.8
CDC42 BPA (MRCKA)	Ser/Thr 13	1	5	Staurosporine	12.7
CDC42 BPB (MRCKB)	Ser/Thr 13	1	5	Staurosporine	13.9
CDC42 BPG (MRCKG)	Ser/Thr 13	2	5	Staurosporine	4.70
CDK1/cyclin B	Ser/Thr 18	34	25	Staurosporine	6.52
CDK17/cyclin Y	Ser/Thr 12	47	50	Staurosporine	19.4
CDK18/cyclin Y	Ser/Thr 12	74	75	Staurosporine	38.5
CDK2/cyclin A	Ser/Thr 12	31	25	Staurosporine	3.15
22.12, 0yomi / t	501, 1111 12	٠.	20	2.aarooponno	0.10



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 35 of 39

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
CDK5/p25	Ser/Thr 12	17	10	Staurosporine	3.60
CDK5/p35	Ser/Thr 12	8	10	Staurosporine	3.98
CDKL5	Ser/Thr 18	516	500	Staurosporine	352
CHEK1 (CHK1)	Ser/Thr 19	53	50	Staurosporine	1.82
CHEK2 (CHK2)	Ser/Thr 07	84	75	Staurosporine	15.7
CLK1	Ser/Thr 09	24	25	Staurosporine	75.3
CLK2	Ser/Thr 06	30	25	Staurosporine	8.62
CLK3	Ser/Thr 18	128	150	Staurosporine	1210
CSF1R (FMS)	Tyr 01	450	500	Tyrphostin AG1478	3470
CSK	Tyr 02	15	10	Staurosporine	56.9
CSNK1A1 (CK1 alpha 1)	Ser/Thr 11	2	5	TBB	9400
CSNK1A1L	Ser/Thr 11	2	5	TBB	12200
CSNK1D (CK1 delta)	Ser/Thr 11	4	5	TBB	2580
CSNK1E (CK1 epsilon)	Ser/Thr 11	2	5	TBB	2630
CSNK1E (CK1 epsilon) R178C	Ser/Thr 11	20	25	TBB	2190
CSNK1G1 (CK1 gamma 1)	Ser/Thr 05	2	5	Chetomin	71.5
CSNK1G2 (CK1 gamma 2)	Ser/Thr 05	5	5	TBB	20500
CSNK1G3 (CK1 gamma 3)	Ser/Thr 05	4.4	5	TBB	45800
CSNK2A1 (CK2 alpha 1)	Ser/Thr 11	4	5	TBB	1950
CSNK2A2 (CK2 alpha 2)	Ser/Thr 11	46	50	TBB	1810
DAPK3 (ZIPK)	Ser/Thr 13	2.5	5	Staurosporine	15.3
DCAMKL1 (DCLK1)	Ser/Thr 23	261	300	Staurosporine	227
DCAMKL2 (DCK2)	Ser/Thr 17	149.5	150	Staurosporine	35.2
DNA-PK	Ser/Thr 26	17	25	PI-103	9.28
DYRK1A	Ser/Thr 18	99.7	100	Staurosporine	27.9
DYRK1B	Ser/Thr 18	86	75	Staurosporine	5.48
DYRK3	Ser/Thr 09	4.7	5	Staurosporine	82.4
DYRK4	Ser/Thr 09	2.2	5	TBB	5260
EEF2K	Ser/Thr 24	15	10	NH125	9940
EGFR (ErbB1)	Tyr 04	11.5	10	Staurosporine	48.3
EGFR (ErbB1) C797S	Tyr 04	2	5	Staurosporine	598
EGFR (ErbB1) G719C	Tyr 04	142	150	Staurosporine	3290
EGFR (ErbB1) G719S	Tyr 04	94	100	Staurosporine	3070
EGFR (ErbB1) L858R	Tyr 04	44.2	50	Staurosporine	58.6
EGFR (ErbB1) L861Q	Tyr 04	12.7	10	Staurosporine	54.5
EGFR (ErbB1) T790M	Tyr 04	10	10	Staurosporine	0.808
EGFR (ErbB1) T790M C797S L858R	Tyr 04	6	5	Staurosporine	1.05
EGFR (ErbB1) T790M L858R	Tyr 04	26	25	Staurosporine	0.409
EPHA1	Tyr 02	18.5	25	Staurosporine	59.7
EPHA2	Tyr 01	65.4	75	Staurosporine	227
EPHA4	Tyr 02	106	100	Staurosporine	70.4
EPHA5	Tyr 01	129	150	Staurosporine	62.1
EPHA8	Tyr 02	123	100	Staurosporine	103
EPHB1	Tyr 02	61.4	50	Staurosporine	86.2
EPHB2	Tyr 02	66	75	Staurosporine	90.4
EPHB3	Tyr 02	70	75	PP2	319
EPHB4	Tyr 01	115	100	Tyrphostin AG1478	1200
ERBB2 (HER2)	Tyr 06	14.1	10	Tyrphostin AG1478	99.7
ERBB4 (HER4)	Tyr 01	5	5	Tyrphostin AG1478	109
FER	Tyr 05	18.5	25	Staurosporine	2.05
FES (FPS)	Tyr 01	30	25	Staurosporine	2.51
FGFR1	Tyr 04	20	25	Staurosporine	5.31
FGFR2	Tyr 04	1	5 5	Staurosporine	2.45
FGFR2 N549H	Tyr 04	1	ວ	Staurosporine	13.6



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 36 of 39

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
FGFR3	Tyr 04	80	75	Staurosporine	29.0
FGFR3 K650E	Tyr 04	6	5	Staurosporine	6.53
FGFR3 V555M	Tyr 04	2	5	Staurosporine	1.08
FGFR4	Tyr 04	162	150	Staurosporine	158
FGR	Tyr 02	10	10	Tyrphostin AG1478	588
FLT1 (VEGFR1)	Tyr 04	158	150	Staurosporine	22.7
FLT3	Tyr 02	470	500	Tyrphostin AG1478	1640
FLT3 D835Y	Tyr 02	18.8	25	Staurosporine	0.309
FLT4 (VEGFR3)	Tyr 04	3.8	5	Staurosporine	4.43
FRAP1 (mTOR)	Ser/Thr 11	11	10	PI-103	26.8
FRK (PTK5)	Tyr 01	51.7	50	Staurosporine	9.50
FYN	Tyr 02	85	75	Tyrphostin AG1478	4990
GRK4	Ser/Thr 16	12	10	Staurosporine	102
GRK5	Ser/Thr 16	3	5	Staurosporine	147
GRK6	Ser/Thr 16	11.7	10	Staurosporine	55.9
GRK7	Ser/Thr 16	10.5	10	Staurosporine	3.65
GSK3A (GSK3 alpha)	Ser/Thr 09	9	10	Staurosporine	13.8
GSK3B (GSK3 beta)	Ser/Thr 09	7	10	Staurosporine	11.7
HCK	Tyr 02	24	25	Tyrphostin AG1478	689
HIPK1 (Myak)	Ser/Thr 09	5	5	TBB	2280
HIPK2	Ser/Thr 09	17	10	Staurosporine	575
HIPK3 (YAK1)	Ser/Thr 18	22	25	TBB	3090
HIPK4	Ser/Thr 18	39	50	Staurosporine	716
IGF1R	Tyr 01	140	150	Staurosporine	141
IKBKB (IKK beta)	Ser/Thr 05	5	5	Staurosporine	425
IKBKE (IKK epsilon)	Ser/Thr 11	16	10	Staurosporine	4.45
INSR	Tyr 01	20	25	Staurosporine	67.7
INSRR (IRR)	Tyr 04	55	50	Staurosporine	99.3
IRAK4	Ser/Thr 07	34	25	Staurosporine	20.8
ITK	Tyr 01	5.6	5	Staurosporine	14.4
JAK1	Tyr 06	87	75	Staurosporine	1.56
JAK2	Tyr 06	31	25	Staurosporine	0.452
JAK2 JH1 JH2	Tyr 06	46	50	Staurosporine	0.797
JAK2 JH1 JH2 V617F	Tyr 06	49	50	Staurosporine	0.702
JAK3	Tyr 06	14	10	Staurosporine	0.801
KDR (VEGFR2)	Tyr 01	78	75	Staurosporine	6.29
KIT	Tyr 06	284	300	Staurosporine	542
KIT T670I	Tyr 06	220	200	Staurosporine	128
KIT V559D	Tyr 06	6	5	Staurosporine	7.36
KIT V559D V654A	Tyr 06	2	5	Staurosporine	8.04
KIT V560G	Tyr 06	5	5	Staurosporine	8.22
KSR2	Ser/Thr 17	15	10	NH125	7250
LCK	Tyr 02	45	50	Tyrphostin AG1478	975
LTK (TYK1)	Tyr 06	82	75 25	Staurosporine	6.18
LYN A	Tyr 02	26	25	Tyrphostin AG1478	287
LYN B	Tyr 02	25	25	Tyrphostin AG1478	205
MAP2K1 (MEK1)	Ser/Thr 03	Cascade	100	Staurosporine	2.48 *
MAP2K2 (MEK2)	Ser/Thr 03 Ser/Thr 03	Cascade	100	Staurosporine	3.08 *
MAP2K6 (MKK6)	Ser/Thr 03 Ser/Thr 07	Cascade	100 5	Staurosporine	3.70 *
MAP3K9 (YSK4)	Ser/Thr 07	5 Cascade	5 100	Staurosporine	12.7 20.6 *
MAP3K8 (COT)	Ser/Thr 03	73		Staurosporine	20.6
MAP3K9 (MLK1) MAP4K2 (GCK)	Ser/Thr 07	73 109	75 100	Staurosporine	0.680
MAP4K2 (GCK) MAP4K4 (HGK)	Ser/Thr 07	109	100	Staurosporine Staurosporine	1.11
14" (1 TICT (1 IOIC)	301/1111 07	12.1	10	Stadiosponiie	1.11



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 37 of 39

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
MAP4K5 (KHS1)	Ser/Thr 07	55	50	Staurosporine	0.796
MAPK1 (ERK2)	Ser/Thr 03	100	100	Staurosporine	1720
MAPK10 (JNK3)	Ser/Thr 04	Cascade	100	Staurosporine	1530 *
MAPK11 (p38 beta)	Ser/Thr 15	39	50	PP2	1970
MAPK12 (p38 gamma)	Ser/Thr 03	16	10	Staurosporine	129
MAPK13 (p38 delta)	Ser/Thr 03	13	10	Staurosporine	285
MAPK14 (p38 alpha)	Ser/Thr 04	Cascade	100	Staurosporine	2880 *
MAPK14 (p38 alpha) Direct	Ser/Thr 15	497	500	PP2	4230
MAPK3 (ERK1)	Ser/Thr 03	45	50	Staurosporine	1950
MAPK7 (ERK5)	Ser/Thr 04	17	10	NH125	6840
MAPK8 (JNK1)	Ser/Thr 04	Cascade	100	Staurosporine	1380 *
MAPK9 (JNK2)	Ser/Thr 04	Cascade	100	Staurosporine	2620 *
MAPKAPK2	Ser/Thr 04	2.5	5	Staurosporine	480
MAPKAPK3	Ser/Thr 04	200	200	Staurosporine	37700
MAPKAPK5 (PRAK)	Ser/Thr 04	14	10	Staurosporine	556
MARK1 (MARK)	Ser/Thr 21	7	5	Staurosporine	27.4
MARK2	Ser/Thr 21	12	10	Staurosporine	28.8
MARK3	Ser/Thr 25	7	5	Staurosporine	0.677
MARK4	Ser/Thr 25	16	10	Staurosporine	0.778
MATK (HYL)	Tyr 01	350	300	Staurosporine	660
MELK	Ser/Thr 17	30	25	Staurosporine	1.74
MERTK (cMER)	Tyr 02	15	10	Staurosporine	16.4
MET (cMet)	Tyr 06	64	50	Staurosporine	96.8
MET (cMet) Y1235D	Tyr 06	31	25	Staurosporine	181
MET M1250T	Tyr 06	14.1	10	Staurosporine	131
MINK1	Ser/Thr 07	26.5	25	Staurosporine	1.61
MKNK1 (MNK1)	Ser/Thr 07	103	100	Staurosporine	178
MST1R (RON)	Tyr 06	10.7	10	Staurosporine	65.8
MST4	Ser/Thr 07	28	25	Staurosporine	4.25
MUSK	Tyr 04	49.5	50	Staurosporine	8.33
MYLK2 (skMLCK)	Ser/Thr 13	310	300	Staurosporine	94.9
NEK1	Ser/Thr 07	118.7	100	Staurosporine	75.9
NEK2	Ser/Thr 07	150	150	Staurosporine	4360
NEK4	Ser/Thr 17	56.2	50	Staurosporine	353
NEK6	Ser/Thr 22	108	100	Chetomin	180
NEK9	Ser/Thr 07	90	100	Staurosporine	1420
NIM1K	Ser/Thr 25	11	10	Staurosporine	337
NTRK1 (TRKA)	Tyr 01	425	400	Staurosporine	4.83
NTRK2 (TRKB)	Tyr 01	22	25	Staurosporine	0.604
NTRK3 (TRKC)	Tyr 01	54	50	Staurosporine	1.68
PAK1	Ser/Thr 19	48.5	50	Staurosporine	1.10
PAK2 (PAK65)	Ser/Thr 20	89	75	Staurosporine	5.76
PAK3	Ser/Thr 20	101	100	Staurosporine	5.44
PAK4	Ser/Thr 20	3	5	Staurosporine	4.28
PAK6	Ser/Thr 20	8	10	Staurosporine	4.33
PAK7 (KIAA1264)	Ser/Thr 20	4	5	Staurosporine	5.92
PASK	Ser/Thr 07	53.3	50	Staurosporine	55.1
PDGFRA (PDGFR alpha)	Tyr 04	9	10	Staurosporine	4.92
PDGFRA D842V	Tyr 04	5.3	5	Staurosporine	5.04
PDGFRA T674I	Tyr 04	93	100	Staurosporine	4.28
PDGFRA V561D	Tyr 04	48	50	Staurosporine	1.14
PDGFRB (PDGFR beta)	Tyr 04	100	100	Staurosporine	5.23
PDK1	Ser/Thr 06	Cascade	100	Staurosporine	8.27 *
PDK1 Direct	Ser/Thr 07	27	25	Staurosporine	7.86



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 38 of 39

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
PEAK1	Tyr 01	56	50	Staurosporine	10.0
PHKG1	Ser/Thr 07	63.3	75	Staurosporine	0.641
PHKG2	Ser/Thr 07	10	10	Staurosporine	1.43
PIM1	Ser/Thr 07	407	400	TBB	1130
PIM2	Ser/Thr 07	3	5	Staurosporine	20.9
PIM3	Ser/Thr 07	818	1000	Staurosporine	3.54
PKN1 (PRK1)	Ser/Thr 07	40	50	Staurosporine	3.24
PLK1	Ser/Thr 16	12.8	10	Staurosporine	560
PLK2	Ser/Thr 16	29.6	25	Staurosporine	313
PLK3	Ser/Thr 16	47.8	50	TBB	1630
PRKACA (PKA)	Ser/Thr 01	4	5	Staurosporine	1.68
PRKCA (PKC alpha)	Ser/Thr 07	37	25	Staurosporine	1.05
PRKCB1 (PKC beta I)	Ser/Thr 07	250	200	Staurosporine	1.57
PRKCB2 (PKC beta II)	Ser/Thr 07	225	200	Staurosporine	0.883
PRKCD (PKC delta) PRKCE (PKC epsilon)	Ser/Thr 07	30 35	25 25	Staurosporine	0.644 4.98
	Ser/Thr 07			Staurosporine	
PRKCH (PKC etc.)	Ser/Thr 07	25 35	25 25	Staurosporine	1.03 1.98
PRKCH (PKC eta)	Ser/Thr 07 Ser/Thr 07	25	25 25	Staurosporine	1.96
PRKCI (PKC iota)	Ser/Thr 17	26 26	25 25	Staurosporine	1.46
PRKCN (PKD3) PRKCQ (PKC theta)	Ser/Thr 07	100	100	Staurosporine	2.25
PRKCZ (PKC zeta)	Ser/Thr 07	4	5	Staurosporine Staurosporine	485
PRKD1 (PKC mu)	Ser/Thr 17	15	10	Staurosporine	3.44
PRKD2 (PKD2)	Ser/Thr 17	27	25	Staurosporine	2.16
PRKG1	Ser/Thr 01	20	25	Staurosporine	3.89
PRKG2 (PKG2)	Ser/Thr 01	177	150	Staurosporine	0.716
PRKX	Ser/Thr 01	17	10	Staurosporine	1.61
PTK2 (FAK)	Tyr 07	45	50	Staurosporine	48.2
PTK2B (FAK2)	Tyr 01	5	5	Staurosporine	11.2
PTK6 (Brk)	Tyr 01	82	75	Staurosporine	833
RAF1 (cRAF) Y340D Y341D	Ser/Thr 03	Cascade	100	Staurosporine	41.3 *
RET	Tyr 02	11	10	Staurosporine	2.79
RET A883F	Tyr 04	10	10	Staurosporine	10.2
RET S891A	Tyr 06	8	10	Staurosporine Staurosporine	0.763
RET V804E	Tyr 04	50	50	Staurosporine .	2.20
RET V804L	Tyr 02	5	5	Staurosporine	2.02
RET Y791F	Tyr 02	12	10	Staurosporine	3.21
ROCK1	Ser/Thr 07	3.1	5	Staurosporine	3.35
ROCK2	Ser/Thr 13	39.5	50	Staurosporine	2.66
ROS1	Tyr 01	61.4	50	Staurosporine	2.17
RPS6KA1 (RSK1)	Ser/Thr 06	6.5	5	Staurosporine	0.717
RPS6KA2 (RSK3)	Ser/Thr 06	8	10	Staurosporine	0.596
RPS6KA3 (RSK2)	Ser/Thr 06	18	10	Staurosporine	0.306
RPS6KA4 (MSK2)	Ser/Thr 01	14.1	10	Staurosporine	3.89
RPS6KA5 (MSK1)	Ser/Thr 01	39	50	Staurosporine	2.11
RPS6KA6 (RSK4)	Ser/Thr 20	30	25	Staurosporine	0.357
RPS6KB1 (p70S6K)	Ser/Thr 07	17	10	Staurosporine	2.60
RPS6KB2 (p70S6Kb)	Ser/Thr 19	44	50	Staurosporine	5.51
SBK1	Ser/Thr 25	3	5	Staurosporine	39.3
SGK (SGK1)	Ser/Thr 06	36	25	Staurosporine	9.79
SGK2	Ser/Thr 06	50	50	Staurosporine	55.3
SGKL (SGK3)	Ser/Thr 06	12	10	Staurosporine	63.8
SNF1LK2	Ser/Thr 25	59 50	50	Staurosporine	0.690
SRC	Tyr 02	50	50	Tyrphostin AG1478	1910



Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 23-Jan-2018

Page 39 of 39

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
SRC N1	Tyr 02	50	50	Tyrphostin AG1478	1230
SRMS (Srm)	Tyr 01	126.9	150	Staurosporine	283
SRPK1	Ser/Thr 18	32	25	Staurosporine	471
SRPK2	Ser/Thr 07	17.6	25	Staurosporine	1530
STK22B (TSSK2)	Ser/Thr 04	3	5	Staurosporine	12.3
STK22D (TSSK1)	Ser/Thr 04	9	10	Staurosporine	0.500
STK23 (MSSK1)	Ser/Thr 18	69	75	Staurosporine	3790
STK24 (MST3)	Ser/Thr 07	56	50	Staurosporine	6.13
STK25 (YSK1)	Ser/Thr 07	83	75	Staurosporine	3.57
STK3 (MST2)	Ser/Thr 07	50	50	Staurosporine	5.61
STK4 (MST1)	Ser/Thr 07	48.9	50	Staurosporine	7.07
SYK	Tyr 02	24.8	25	Staurosporine	0.549
TAOK2 (TAO1)	Ser/Thr 07	322	300	Staurosporine	16.2
TBK1	Ser/Thr 05	35	25	Staurosporine	1.90
TEK (Tie2)	Tyr 05	16.7	10	Staurosporine	71.5
TEK (TIE2) Y897S	Tyr 06	207	300	Staurosporine	234
TNK1	Ser/Thr 13	237	200	Staurosporine	3.52
TXK	Tyr 06	96	100	Staurosporine	43.0
TYK2	Tyr 03	23	25	Staurosporine	1.01
TYRO3 (RSE)	Tyr 02	27.7	25	Staurosporine	7.39
YES1	Tyr 02	20.3	25	Tyrphostin AG1478	863
ZAP70	Tyr 07	2	5	Staurosporine	489